ArticleAntonie van Leeuwenhoek2026
Antimicrobial and probiotic potential of Lactobacillus from traditional dairy products against uropathogenic gram-negative bacteria.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are among the most prevalent bacterial infections and are increasingly complicated by the emergence of multidrug-resistant uropathogens. The present study investigated the probiotic potential and anti-uropathogenic activity of Lactobacillus strains isolated from traditional dairy products in western Algeria using combined in vitro screening and an in vivo rat model of UTI. Uropathogenic bacteria recovered from urine samples of female patients were identified as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Proteus vulgaris using standard microbiological methods and the API 20E identification system. Sixteen lactic acid bacteria isolated from raw milk and fermented dairy products were characterized phenotypically and identified by API 50 CHL and 16S rDNA sequencing as Lactobacillus acidophilus (n = 5), Limosilactobacillus fermentum (n = 4), Levilactobacillus brevis (n = 5), and Lactobacillus delbrueckii subsp. lactis (n = 2). In vitro assays demonstrated strain-dependent variations in cell surface hydrophobicity, autoaggregation, and phenol tolerance among the isolates. Most isolates showed susceptibility or intermediate responses to several clinically relevant antibiotics, while resistance was mainly observed to vancomycin, penicillin G, piperacillin, and nalidixic acid. Agar well diffusion assays revealed inhibitory activity against the principal uropathogens, with the strongest inhibition observed against E. coli. Two selected strains (L. acidophilus and L. fermentum) were further evaluated through intravesical administration in rats. The in vivo efficacy was strictly dependent on the frequency of administration; notably, a single-dose treatment was completely ineffective and failed to control leukocyturia or reduce pathogen colonization. In sharp contrast, precolonization followed by repeated instillations led to a dramatic clearance of the pathogen by day 11, reducing urinary E. coli counts down to 49 CFU/mL for L. acidophilus and 356 CFU/mL for L. fermentum. This repeated regimen also significantly controlled the inflammatory host response, with leukocyte counts decreasing from greater than 10
Indexed as
Identifiers
42720793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.